Taking people in FranceNo phase

Tests psychomotor therapy with usual treatment for depression

Tests psychomotor therapy with usual care in adults with depression.

Key facts

Who runs it: Centre Hospitalier Esquirol
Where: Limoges, FranceSee the site
Trial code: NCT06234176
Registry title: Impact of Psychomotor Therapy on the Quality of Life in Depression
Status: Recruiting
People taking part: 128 people, planned
Started: 1 Apr 2024
Expected to end: Nov 2027
Type of study: Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested: Personalised psychomotor therapy
Usual treatment
Record updated: 30 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 20 to 60 with major depression. It tests whether weekly psychomotor therapy added to usual treatment improves quality of life.

Age: 20 to 60 years
Sex: All sexes can join.
Disease stage: A depressive episode as defined in DSM-5, with an HDRS score above 16. Hospitalized or followed-up in one of the participating centers.

Main reasons for not taking part

Another psychiatric condition, such as non-tobacco addiction, eating disorder, bipolar disorder, obsessive-compulsive disorder or schizophrenia
Sensory impairment, proven neurological disease, or past brain damage
Limited ability to move about or do manual tasks
Pregnant or breast-feeding women
Forced hospitalization, guardianship or trusteeship, or no social protection

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

Diagnosis of depressive episode according to DSM-5 criteria
HDRS > 16
Hospitalized or followed-up in one of the participating centers
Affiliated or beneficiary of a social security scheme
Free, informed and written consent signed by the participant and the investigator (no later than the day of inclusion and before any examination required by the research)

Who cannot take part

Psychiatric comorbidity (non-tobacco addiction, eating disorders, bipolar disorder, obsessive-compulsive disorder, schizophrenia and related disorders)
Sensory impairment or proven neurological pathology
History of neurological brain damage (including stroke, tumor, trauma resulting in loss of consciousness lasting more than 10 minutes)
Limited functional ability (difficulty in moving about, performing manual tasks or moving about)
Inability to understand questionnaires and study information
Inability to travel to the inclusion center (personal vehicle, public transport)
Pregnant or breast-feeding women, on declaration
Forced hospitalization, subjects under guardianship or trusteeship, lack of social protection

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

Are you between 20 and 60 years old?

Where in France

CH EsquirolLimoges, FranceContact: Aude PAQUETTaking people

About the trial

What the trial wants to find out

The effectiveness of psychomotor therapy in improving clinical outcomes or quality of life for individuals with depression is unclear.

Read full original descriptionShow less

The investigators will assess how the participants' quality of life and psychomotor profile change over time.

The study aims to compare the quality of life at 3 months between patients who received 3 months of personalised psychomotor therapy in addition to standard treatment and those who received standard treatment alone.

The study lasted for 6 months, and the investigators expects a total of 128 people to participate in this research across several hospital establishments. This study evaluates the effectiveness of two types of treatment, divided into two randomly selected groups.

To participate, individuals must have a medical diagnosis of major depressive disorder (MDD) and be between the ages of 20 and 60.

They must have depressive symptoms with an HDRS score greater than 16 and provide informed consent. They must be treated or hospitalised at the Centre Hospitalier Esquirol or the Centre Hospitalier Henri Laborit (France).

After providing consent, they will undergo an initial clinical interview that evaluates anxiety, self-esteem, pleasure, and quality of life. The therapist assessed the participant's muscle tone, gross motor skills, praxis, manual dexterity, rhythm, processing of sensory information, and body image.

Following the assessment, the participant was randomly assigned to either the experimental or control group.

The experimental group received the usual treatment for depression and underwent psychomotor therapy once a week for 12 weeks.

The control group received the standard treatment for depression and underwent weekly telephone interviews.

An assessment is scheduled at 1 month to evaluate the participant's health status, including any changes to treatment and assessment of anxiety and depressive symptoms.

Another interim check-up is scheduled at 3 months to assess the patient's health status. The interview will also assess any changes to treatment, anxiety and depressive symptoms, quality of life, and psychomotor function.

A final visit will be scheduled at 6 months for an assessment of the participant's health. The interview will also assess any changes to treatment, anxiety and depressive symptoms, quality of life, and psychomotor function.

The 2 groups in the trial

Personalised psychomotor therapy groupTreatment being tested
1 psychomotor therapy session of 45 minutes per week for 12 weeks + Duke Health Scale.
Treatment: Personalised psychomotor therapy
Usual treatment groupExisting treatment, for comparison
Standard treatment for depression administered by a doctor + a weekly telephone interview for 12 weeks to administer the Duke Health Scale.
Treatment: Usual treatment